9E1B image
Deposition Date 2024-10-21
Release Date 2024-10-30
Last Version Date 2025-06-25
Entry Detail
PDB ID:
9E1B
Title:
Structure of RyR1 in the open state in the presence of dyphylline
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
4.49 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Ryanodine receptor 1
Gene (Uniprot):RYR1
Chain IDs:A, F (auth: B), G (auth: D), H (auth: C)
Chain Length:5037
Number of Molecules:4
Biological Source:Oryctolagus cuniculus
Polymer Type:polypeptide(L)
Molecule:Peptidyl-prolyl cis-trans isomerase FKBP1A
Gene (Uniprot):FKBP1A
Chain IDs:B (auth: E), C (auth: H), D (auth: G), E (auth: F)
Chain Length:108
Number of Molecules:4
Biological Source:Oryctolagus cuniculus
Primary Citation
Targeting ryanodine receptors with allopurinol and xanthine derivatives for the treatment of cardiac and musculoskeletal weakness disorders.
Proc.Natl.Acad.Sci.USA 122 e2422082122 e2422082122 (2025)
PMID: 40512792 DOI: 10.1073/pnas.2422082122

Abstact

Ryanodine receptors (RyRs) are intracellular Ca2+ channels essential for muscle contraction. Caffeine, a xanthine derivative, has been known for decades to increase muscle contraction and enhance activation of RyRs by increasing the sensitivity to Ca2+. We previously showed that xanthine, the only physiologically relevant xanthine derivative, also binds to and activates RyR2. Most xanthine derivatives and analogs are safe and widely prescribed, with the most popular being the xanthine oxidoreductase inhibitor allopurinol (~15M yearly prescriptions in USA). We propose that xanthine derivatives and analogs that enhance RyRs activity could be used for lead optimization and eventually for the treatment of the diseases that exhibit decreased muscle contraction and reduced RyRs activity, such as RyR1-related diseases, sarcopenia, and heart failure. Here, we show by cryo-EM that xanthine derivatives, analogs, and other related compounds bind to the xanthine/caffeine binding site and activate RyR1, and identify 4-oxopyrimidine as the minimal motif necessary for such interaction.

Legend

Protein

Chemical

Disease

Primary Citation of related structures